Insulet | PODD - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 5.86B 675M 2026-03
Align Technology USD 736.59M 53M 2026-03
AtriCure USD 109.31M 3.97M 2026-03
Avanos Medical USD 94.2M 8.2M 2026-03
Baxter International USD 891M 314M 2026-03
Becton, Dickinson and Co. USD 2.15B 257M 2026-03
Boston Scientific USD 3.61B 64M 2026-03
Cardinal Health USD 2.5B 101M 2026-03
Cooper Companies USD 735.4M 40.2M 2026-03
Dexcom USD 750.3M 42.4M 2026-03
Edwards Lifesciences USD 1.29B 59.4M 2026-03
Eli Lilly USD 15.92B 1.33B 2025-12
Globus Medical USD 496.26M 39.69M 2026-03
ICU Medical USD 202.98M 2.1M 2025-12
Inogen USD 41.34M 1.39M 2024-09
Insulet USD 540.8M 27.8M 2026-03
Integra LifeSciences USD 213.21M 3.89M 2026-03
J&J USD 17.24B 642M 2026-03
Medtronic USD 6.01B 595M 2026-03
Merit Medical Systems USD 184.8M 10.56M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Solventum Corp USD 1.1B 70M 2026-03
Stryker USD 3.81B 675M 2026-03
Tandem Diabetes Care USD 167.46M 33.17M 2025-12
Teleflex USD 307.43M 21K 2026-03
West Pharmaceutical Services USD 296.4M 7.5M 2026-03
Zimmer Biomet Holdings USD 1.27B 8.1M 2025-12